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Summary.-The blastogenic response ofautologous blood lymphocytes to whole-cell
suspensions and to homogenates obtained from malignant lymphoma tissue has been
investigated. Spleens were obtained from patients in whom laparotomy was
performed for staging of malignant lymphoma. Cell suspensions prepared from
tumour nodules were treated with mitomycin C and allowed to react with separated
autologous blood lymphocytes for 6 days. Lymphocyte stimulation was measured
by liquid scintillation counting after exposure to 3H-TdR. Cultures were also
prepared in which autologous lymphocytes were treated with spleen tumour homo-
genate. Control experiments used spleens from staging procedures in which no
tumour deposits were present, and normal spleens removed incidentally during
other operations.
In the controls, the uptake of TdR was never more than twice that ofunstimulated
lymphocytes. Greater degrees of lymphocyte stimulation were seen in 6 out of 14
patients, using whole tumour cells, and in 7 out of 16 patients, using tumour homo-
genates. The results indicate an antigenic difference between tumourand hostcells,
and suggest that lymphocytes can react to a tumour-associated antigen.
MANY human tumours have been
shown to have antigenic differences
from normal autologous cells (Lewis,
1967; Morton et al., 1968; Helistrom et al.,
1971). Immunization to these antigens
may occur in vivo (Powles, Balchin and
Fairley, 1971) and sensitized lymphocytes
may be detected by a blastogenic response
on confrontation with whole tumour cells
or tumour extracts (Mavligit et al., 1973;
Vanky et al., 1974), using methods similar
to those used in a one-way mixed lympho-
cyte reaction (Bach and Voynow, 1966).
Positive reactions have been observed in
various types of carcinoma, sarcoma,
malignant melanoma and leukaemia.
We thought that similar investigations
wouldbe ofvalueinmalignantlymphomas,
especially in view of the variety of cell
types seen in histological examination of
Hodgkin's disease, in which some almost
certainly represent host activity. We
have therefore investigated the response
of autologous lymphocytes to lymphoma
cell suspensions and to subcellular pre-
parations oflymphoma tissue.
MATERIALS AND METHODS
Patients.-Spleens were obtained from
patients in whom laparotomy was performed
in order to stage the anatomical extent of
malignant lymphoma or to provide the initial
diagnosis, from patients in whom the spleen
was removed for other non-neoplastic haema-
tological diseases, and from patients in whom
a histologically normal spleen was removed
during the course of another operation (e.g.
resection of carcinoma of the stomach).
Lymph node tissue was also used on one
occasion. All patients were untreated for
malignant disease.
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All tissues were examined histologically,
and both focal nodules, ifpresent, and macro-
scopically normal areas of spleen were
sampled. The Rye Symposium classification
was used for Hodgkin's disease (Lukes et al.,
1966b) and Rappaport's classification was
adopted for other lymphomas (Rappaport,
1966).
Tissue cell suspensions.-0-5 g of tissue
was finely minced with scissors and forceps
in TC 199 (Wellcome Reagents Ltd.) con-
taining 15% heat-inactivated foetal calf
serum (FlowLaboratories Ltd.). Anytumour
nodules were dissected to include as little
adjacent spleen as possible. The final
volume was made up to 50 ml, transferred to
a sterile 250-ml Erlenmeyer flask with a loose
seal, which was placed in a Mackintosh jar,
gassed with 5% Co02 in air, and maintained at
370C until utilized. The cell suspension was
counted, and its viability assessed by trypan
blue exclusion, the viability always being
> 65%.
Tissue cell homogenates.-5 g oftissue was
sliced in 25 ml sterile 0.9% saline, homo-
genized for 15 x 1 min in a sterile MSE
atomixer, with water cooling between each
burst, and stored at -70°C. Homogenates
were checked for bacteriological contamina-
tion.
Cell reactions.-20 ml of venous blood,
anticoagulated with 200 u of preservative-
free heparin, was layered on a sterile gradient
composed of 9-6 ml of 9% Ficoll (Pharmacia
Fine Chemicals) and 4 ml of a solution of
Triosil 440 (Nyegaard and Co.) prepared by
adding 24 ml water to 20 ml Triosil. The
gradient was centrifuged at 600g for 30 min,
and the lymphocytes at the interface were
removed, washed x 3 in 0.9% sterile saline,
and resuspended in culture medium. The
cells were counted and assessed for viability,
which was always > 90%.
Triplicate 1-ml cultures were set up in
tissue culture test tubes, with a final cell
concentrationof106lymphocytes/ml inculture
medium. Autologous spleen homogenates in
protein concentrations of 10-100 ,ug/ml were
added to the test cultures. Control cultures
contained lymphocytes alone. Heterologous
responses, in which spleen homogenates were
used to stimulate lymphocytes from normal
individuals were also tested.
In the mixed-cell reaction, triplicate 1-ml
cultures with equal numbers of peripheral
lymphocytes and tissue cells were used at a
final concentration of 106 ofeach cell type/ml.
The tissue cell suspensions were treated with
0-25 ,ug/ml mitomycin C (Kyowa Hakko
Kogyo Co., Ltd.) at 37°C for 20 min, washed
x 5 in sterile 0-9% saline, and resuspended
in culture medium. Two types of control
cultures were set up: (a) blood lymphocytes
alone and (b) mitomycin-treated tissue cells
alone. Cultures were maintained at 37°C for
6 or 7 days, 0-2 uCi/ml of 3H-TdR (Radio-
chemical Centre, Amersham) being present
during the last 8 or 16 h of culture. The
duration of culture and of exposure to 3H-
TdR was always identical in test and control
cultures for any one experiment.
Blood lymphocytes were also treated with
phytohaemagglutinin (PHA, reagent grade,
0-01 ml/ml) at the same time as carrying out
other experiments, in order to test the
efficiency of the culture system rather than
obtaindetailedinformationonPHAresponse.
These cultures were generally harvested after
3 or4days, whenmaximal stimulationis seen.
The cells were harvested, washed X 3 in
0.9% saline, and precipitated with 5%
trichloracetic acid, the precipitates being
collected via a millipore sampling manifold
on glass filter paper discs (Whatman GF-C),
which were then washed with 5% trichlor-
acetic acid followed by absolute ethanol.
The discs were dried and placed in a
plastic scintillation vial containing 10 ml of
scintillation fluid, comprised of PPO, 5g;
POPOP, 041 g; and 0-2 ml of hyamine
hydroxide, in 1 litre oftoluene. Thevials were
counted in a Packard Scintillation Counter
for a minimum of 10 min or 10,000 counts,
whichever was first obtained, and the results
expressed as ct/min.
A stimulation index (SI) similar to that
used by Mavligit et al. (1973) was calculated
as follows: for homogenate or PHA-treated
cultures, SI was defined as the mean ct/min
in the treated cultures, divided by the mean
ct/min in the untreated controls. For the
mixed cell reactions, SI was defined as:
(ct/min of 106 blood lymphocytes mixed with
106 mitomycin-treated tissue cells-ct/min
of 106 mitomycin-treatedtissue cellsalone)
ct/min of 106 untreated blood lymphocytes.
RESULTS
Mixed-cell reactions
In patients with malignant lymphoma
in whom the spleen or lymph node was
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TABLE L.-Hodgkin's and Other Diseases: Tissue free of Tumour
Patient Diagnosis
(a) Hodgkin's Disease; tissue free of tumour
S.I. Nodular sclerosing
S.M. Nodular sclerosing
G.W. Mixed cellularity
lJ.M. Mixed cellularity
A.W. Nodular sclerosing
L.W. Nodular sclerosing
H.M.
J.R.
I.O.
A.S.
W.H.
D.I.
(b) Other
M.W.
C.P.
Mixed cellularity
Nodular sclerosing
Nodular sclerosing
Nodular sclerosing
Lymphocytic predominant
Mixed cellularity
non-neoplastic spleens
Cholecystitis
Hypersplenism
(reactive hyperplasia)
Stimulation
Index (SI)
Tissue (mixed-cell
Age Sex source cultures)
29
28
57
23
31
54
63
39
30
23
57
36
F
F
M
M
F
M
M
F
F
M
M
M
Spleen
Spleen
Spleen
Spleen
Spleen
Lymph
node
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
66 F Spleen
64 F Spleen
0 3
0 4
0 5
0 5
1 4
0-6
1 *6
0 4
0 4
free oftumour, and in other non-neoplastic
spleens (Table I), the stimulation index
ranged from 0 4 to 1P6 with a mean of 0 7
(s.d. 0.47). From tables for " t " values
it is calculated that 9500 of results would
be less than 1P5. A more conservative
figure of 2.0 or above was taken to
indicate a positive result, and all control
values fell below this.
When lymphoma tissue was present in
the spleen, 6 out of 14 patients (430o)
showed a positive response (Table II,
Fig.). The indices of 4-8, 20-6 and 6-2
are highly significant (P < 0-001), the
first 2 being obtained from nodular
sclerosing Hodgkin's disease, and the
third from follicular lymphoma oflympho-
cytic type. The 3 indices of 2-2 were
TABLE II. Malignant Lyrnphomas: Tumour Present in Tissue
Patient Diagnosis
(a) Hodgkin's disease
P.D. Mixed cellularity
D.L. Nodular sclerosing
G.B. Mixed cellularity
D.G. Nodular sclerosing
M.M. Nodular sclerosing
M.H. Lymphocyte depleted
A.M. Nodular sclerosing
A.K. Mixed cellularity
W.H. Mixed cellularity
W.C. Nodular sclerosing
S.H. Nodular sclerosing
(b) Other lymphomas
P.W. Lymphocytic lymphoma
(well differentiated)
B.G. Lymphocytic lymphoma
(well differentiated)
C.N. Lymphocytic lymphoma
(poorly differentiated)
G.A. "Histiocytic " lymphoma
T.D. Lymphocytic lymphoma
(well differentiated)
B.C. Lymphocytic lymphoma
(follicular)
J.M. " Histiocytic " lymphoma
D.T. Lymphocytic lymphoma
Tissue
Age Sex source
36
33
21
31
42
21
40
29
45
63
23
M
F
M
M
F
M
M
M
M
M
F
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
49 F Spleen
62 F Spleen
33 F Spleen
50 F Spleen
62 M Lymph node
50 F Spleen
60 F Spleen
50 M Spleen
SI (mixed-cell
culture)
0-6
4-8
2-2
20-6
0 9
0*5
0-8
0 7
2- 1
0 7
0-6
6-2
2-2
0 4
SI (homogenate-
treated cultures)
7 0
18-0
1 4
1 *6
1-8
1-1
0 5
1 *4
0-6
2-3
0-6
2-3
0-6
2-3
4-5
0 4
SI
(homogenate-
treated
cultures)
1*95
1*4
0 7
0 9
1*5
1*2
1.0
0-6
0 9
1*5
0-8
0 7
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20
10
5
Stimulation
Index
2
05
0
0
I
0
A
20
10.
5'
2.
05.
0
III
B
0
0
~r
S.
C 0
FiG.-Response of autologous lymphocytes to stimulation (SI) by: A, whole cells from control
spleens; B, whole cells from tumour deposits; C, homogenate of control spleens; D, homogenate of
tumour deposits.
obtained from well-differentiated lympho-
cytic lymphoma, lymphocyte-depleted
Hodgkin's disease and " histiocytic " lym-
phoma.
Homogenate-treated cultures
Withtumour-free spleens from patients
with malignant lymphoma and with other
non-neoplastic spleens (Table I), the
stimulation index ranged from 0-6 to 1*9
with a mean of 1 1 (s.d. 0.4). From " t "
tables, 9500 of these control values would
be expected to be 1P8 or below, so an index
of 2-0 or above was regarded as positive,
as for the mixed-cell reactions, and all
control figures fell in the negative range.
Positive reactions were seen in 7 out of
16 patients (440%) in whom tumour was
present in the spleen (Table II, Fig.).
The indices of 18-0, 7 0 and 4-5 are highly
significant (P < 0-001) and are from
nodularsclerosingHodgkin's disease,mixed
cellularity Hodgkin's disease and lympho-
cytic lymphoma. The 2 figures of 2-3 are
significant at the 1% level, and relate to
nodular sclerosing Hodgkin's disease and
lymphocytic lymphoma. The SI of 2-0
was from nodular sclerosing Hodgkin's
disease, and is significant at the 5% level.
Phytohaemagglutinin-treated cultures
PHA-treated cultures invariably
showed some degree of stimulation, with a
maximum of 42,000 ct/min and an SI
ranging from 2-0 to 180. A detailed
protocol of one experiment is provided in
Table III.
Heterologous reactions
Using a panel of 10 normal donors,
positive reactions were obtained in a total
of 34 out of 99 tests (340) in which allo-
TABLE III.-Patient A.M., Nodular
Sclerosing Hodgkin's Disease withSplenic
Deposits. Testing of Spleen Cell Sus-
pension
ct/min
(mean of
3 cultures)
Blood lymphocytes alone 170 (3 days)
80 (7 days)
Blood lymphocytes + PHA 8200 (3 days)
Blood lymphocytes + mitomycin- 1700 (7 days)
treated spleen cells
Mitomycin-treated spleen cells alone 50 (7 days)
SI (PHA) 8200 48-2 170
SI (spleen cells) 1700 50 =20 6 80
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geneic lymphocytes were treated with a
range of spleen homogenates. When
tumour was present in the spleen extract,
21 out of 69 (30%) were positive (SI
2*1-44, mean 10'5). With tumour-free
splenic extracts, 13 out of 30 tests (43%)
were positive (SI 3-2-50, mean 17.2).
DISCUSSION
The results demonstrate significant
autologous lymphocyte blastogenesis, in
response to both suspended lymphoma
cells and tumour homogenates, compared
with the effects of similar preparations of
non-malignant spleens. The present in-
vestigation has concentrated exclusively
on malignant lymphomas, but the results
are comparable with those obtained from
studies of other solid tumours. Lym-
phocyte stimulation was demonstrated in
10 out of 18 patients with various non-
lymphomatous malignant tumours, in
response to whole tumour cells, and 9 of
the 10 patients with positive reactions
also responded to in vitro stimulation with
a potassium chloride extract of tumour
tissue (Vanky et al., 1974). In a similar
analysis, 19 out of 29 patients with
malignant tumours, which included a few
lymphomas, showed positive reactions
between tumour cells and patient's lym-
phocytes (Mavligit et al., 1973) and 2
patients responded to a tumour extract.
A smaller proportion of positive results
was found by Savel (1969), who obtained
significant stimulation in 7 patients out of
56, using a saline extract of tumour; 6
lymphomas of unspecified type were
amongst the negative responders and no
lymphomas were positive. Positive in
vitro reactions have been found in lympho-
sarcoma and Hodgkin's disease, using the
M.I.F. method (Braun et al., 1972).
In experimental situations of the type
we have investigated, a useful control
would be to compare the effects oftumour
cells and normal cells from the same organ.
This is possible if there are reasonably
large areas of tumour-free spleen, in
addition tothe presence oftumournodules.
Our experience to date has been that
whenever large dissectable tumour nodules
have been present, small nodules have
usually been present in the intervening
splenic tissue, with the result that it has
been possible to perform this control on
one occasion only. In this instance, both
tumour-containing and tumour-free areas
responded negatively.
In the present study, 11 out of 19
patients had a positive response in at least
one ofthe tests employed. It is ofinterest
that of these 11 positive results, 4 were
from patients with nodular sclerosing
Hodgkin's disease, and only 2 patients
with nodular sclerosis had a negative
result (Table II). The numbers are too
small to draw any definite conclusions in
relation to individual histological types,
but it is of note that nodular sclerosis is
one of the subvarieties of Hodgkin's
disease carrying a better prognosis than
average (Lukes, Butler and Hicks, 1966a;
Gough, 1970).
Possible explanations for the reactions
are: (a) that blastogenesis occurs in
lymphocytes which were presensitized in
vivo to an antigenic component of the
tumour cell; (b) that lymphocytic stimu-
lation represents a primary immune re-
action to a tumour-associated antigen; (c)
that lymphocytic stimulation is caused by
a non-specific mitogen of no immuno-
logical significance.
The third explanation could not apply
to the mixed-cell reaction, and appears
very unlikely in the case oftissue extracts,
in view of the fact that no significant
stimulation occurs using extracts ofnormal
autologous spleen.
In the mixed-cell reactions, it is not
possible to be certain whether a primary or
secondary immune reaction is at work, but
the latter appears at least to contribute, in
view of the finding that the blastogenic
response to leukaemic cellscanbeincreased
byimmunizationwithirradiatedleukaemic
cells during remission (Powles et al., 1971).
It has been generally thought that
subcellular preparations of disrupted cells
stimulate allogeneic lymphocytes poorly
or not at all (Hardy, Ling and Knight,
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1969), and that lymphocytic blasto-
genesis to a solubilized extract represents
a secondary immune response. The
situation with tumour extracts is more
complicated, in that while some investi-
gators found that tumour extracts do
not produce stimulation of normal
lymphocytes (Jehn, 1970; Vanky et al.,
1974), Dean et al. (1975) have recently
demonstrated that breast carcinoma ex-
tracts can stimulate lymphocytes from
normal individuals. They regarded this
as a primary immune response to normal
alloantigens in the extract, and concluded
that investigation of blastogenic responses
to breast carcinoma should be restricted to
autologous situations. Similar results
are evident from the present study, in
which blastogenesis can be induced in
normal allogeneic lymphocytes by spleen
extracts with or without tumour deposits.
As no significant stimulation occurs in
autologous lymphocytes in response to
tumour-free splenic extracts, the inter-
pretation that autologous blastogenesis
produced by tumour-containing extracts
represents animmunologicalevent,remains
valid, but it is not possible to distinguish
between a primary and secondary immune
response. The leucocyte migration inhibi-
tion factor assay is influenced by allo-
antigens to a lesser degree (McCoy et al.,
1974), and may prove to be a more suitable
index of heterologous reactions.
The degree of lymphocytic stimulation
by whole tumour cells and homogenates is
less than that obtained by stimulation
with allogeneic lymphocytes, with some
individual exceptions (Powles et al., 1971),
indicating that, generally speaking, the
antigenic difference between tumour cells
and autologous somatic cells is less than
the antigenic difference between cells of
unrelated individuals. It appears, how-
ever, that at least in leukaemia, the
difference is sufficient to make immuno-
therapy using killed autologous tumour
cells a realistic proposition (Powles et al.
1973).
If immunotherapy using tumour cells
or extracts should be considered for the
therapy of malignant lymphomas, labora-
tory evidence of immunological differ-
ences between host and tumour cells is a
useful prerequisite to providing a rational
basis for treatment.
This work was supported by Clinical
Research Grant CL177 provided by the
South Glamorgan Area Health Authority.
We are grateful to Dr J. Whittaker and
Mr D. Crosby for allowing us to investigate
patients under their care.
REFERENCES
BACH, F. H. & VoyNow, N. K. (1966) One Way
Stimulation in Mixed Leucocyte Cultures. Science,
N.Y., 153, 545.
BRAUN, M., SEN, L., BACHMANN, A. E. & PAVLOVSKY,
A. (1972) Cell Migration Inhibition in Human
Lymphomas using Lymph Node and Cell-line
Antigens. Blood, 39, 368.
DEAN, J. H., SILVA, J. S., McCoy, J. L., LEONARD,
C. M., MIDDLETON, M., CANNON, G. B. & HERBER-
MAN, R. B. (1975) Lymphocyte Blastogenesis
Induced by Potassium Chloride Extracts of
Allogeneic Breast Carcinoma and Lymphoid Cells.
J. natn. Cancer Inst., 54, 1295.
GOUGH, J. (1970) Hodgkin's Disease; a Correlation
of Histopathology with Survival. Int. J. Cancer,
5, 273.
HARDY, D. A., LING, N. R. & KNIGHT, S. C. (1969)
Exceptional Lymphocyte Stimulating Capacity of
Cells from Lymphoid Cell Lines. Nature, Lond.,
223, 511.
HELLSTROM, I., HELLSTROM, K. E., SJOGREN, H. 0.
& WARNER, G. A. (1971) Demonstration of Cell
Mediated Immunity to Human Neoplasms of
Various Histological Types. Int. J. Cancer, 7, 1.
JEHN, V. W. (1970) In vitro Lymphocyte Stimulation
by a Soluble Antigen from Malignant Melanoma.
New Enyl. J. Med., 283, 329.
LEWIS, M. G. (1967) Possible Immunological
Factors in Human Malignant Melanoma in
Uganda. Lancet, ii, 921.
LUKES, R. J., BUTLER, J. J. & HICKS, E. B. (1966a)
Natural History of Hodgkin's Disease as Related
to its Pathological Picture. Cancer, N. Y., 19, 317.
LUKES, R. J., CRAVER, L., HALL, T., RAPPAPORT, H.
& RUBEN, P. (1966b) Report of the Nomenclature
Committee, Symposium on the Obstacles to the
Control of Hodgkin's Disease. Cancer Res., 26,
1311.
McCoy, J. L., JEROME, L. F., DEAN, J. H., CANNON,
G. B., ALFORD, T. C., DOERING, T. & HERBERMAN,
R. B. (1974) Inhibition of Leukocyte Migration
by Tumour-associated Antigens in Soluble Ex-
tracts of Human Breast Carcinoma. J. natn.
Cancer Inst., 53, 11.
MAVLIGIT, G. M., GUTTERMAN, J. U., McBRIDE,
C. M. & HERSH, E. M. (1973) Cell Mediated
Immunity to Human Solid Tumours: In vitro
Detection by Lymphocyte Blastogenic Responses
to Cell Associated and Solubilized Tumour
Antigens. Natn Cancer Inst. Monogr., 37, 167.BLASTOGENIC RESPONSE TO AUTOLOGOUS LYMPHOMA 625
MORTON, D. L., MALMGREN, R. A., HOLMES, E. C. &
KETCHAM, A. S. (1968) Demonstration of Anti-
bodies against Human Malignant Melanoma by
Immunofluorescence. Surgery, 64, 233.
PowLEs, R. L., BALCHIN, L. A. & FAIRLEY, G. H.
(1971) Recognition of Leukaemic Cells as Foreign
Before and After Auto-immunization. Br. med.
J., i, 486.
POWLES, R. L., CROWTHER, D., BATEMAN, C. J.,
BEARD, M. E., McELWAIN, T. J., RUSSELL, J.,
LISTER, T. A., WHITEHOUSE, J. M., WRIGLEY,
P. F., PIKE, M., ALEXANDER, P. & FAIRLEY, G. H.
(1973) Immunotherapy for Acute Myelogenous
Leukaemia. Br. J. Cancer, 28, 365.
RAPPAPORT, H. (1966) Tumours ofthe Haematopoietic
Sy8tem. Armed Forces Institute of Pathology.
SAVEL, H. (1969) Effect of Autologous Tumour
Extracts on Cultured Human Peripheral Blood
Lymphocytes. Cancer, N.Y., 24, 56.
VANKY, F., KLEIN, E., STJERNSWARD, J. & NIL-
SONNE, U. (1974) Cellular Immunity Against
Tumour Associated Antigens in Humans: Lym-
phocyte Stimulation and Skin Reaction. Int. J.
Cancer, 14, 277.